of course you don't see it ---- you're a dope... we would not expect you to understand any difference between prior inhaled insulins. The reasons for prior failures are well documented and do not apply to Afrezza...
colton_harden1, in your future posts please preface your remarks with "I'm not a smart man, but...." Your constant posting reminds me of Forest Gump's running for a year for reasons only he might have understood.
man, i'm not diabetic. but this thing is approved. warning label not that bad. and if i was diabetic, even if this was the treatment i could only use 'part of the time,' i don't know, it sure beats the heck out of jabbing yourself with a needle. it's a convenient and pretty revolutionary treatment, and it's only a matter of time till it hits the market and makes money. this is no longer speculation and theres no smoke and mirrors, it's coming, and the lt trend is gonna be up, believe it.
For starters a major M&A firm like Greenhill doesn't take on a client to fail. Then you have the ADA. As they said at the Adcom they rarely support new drug applications. However, since they thought Afrezza was so significant they publicly asked the FDA to approve it during public comment. Then you have the JDRF, they too asked for the FDA to approve. Now, when has that ever happened before? Moreover, if Nektar could get a major BP to partner with a bad product, what do you think MNKD can do with a paradigm shifting product? The question is not about getting a partner its all about picking the correct partner with the best deal for MNKD, Afrezza and Technosphere. This was the reason Greenhill was brought in.
Each day that passes post FDA approval with no partnership announcement has to scare everyone. Clearly the interest that Mannkind wants is not what people are giving them. No excuses anymore for why there isn't an announcement right?